Introduction
cancer screening include: cytology (Papanicolaou smear); visual methods (visual inspection with acetic acid (VIA) and Lugol's iodine (VILI)); and HPV DNA-based detection tests. The merits and limitations of these methods are summarized in Table 1 .
Cervical cytology
Papanicolaou smear has been the cornerstone of well-organized population-based screening programs demonstrating remarkable success in reducing the incidence and mortality from cervical cancer in developed nations (Arbyn et al., 2009) .
The World Health Organization has observed that incidence and mortality from cervical cancer can be significantly reduced by ensuring even once in a lifetime Pap smear-based screening of every eligible woman, ideally between 35-45 years of age (Stjernsward et al., 1987; WHO, 2002) . The major strengths of cytology-based screening have been the inherent simplicity, relatively low cost and large knowledge base of various cytologic patterns of precancerous lesions (Tambouret, 2013) . Though the sensitivity of cervical cytology is low, its specificity is quite high (60-95%) for detection of CIN2+ lesions (Nanda et al., 2000) . Few recently published meta-analyses have also reaffirmed the high specificity and moderate sensitivity of cytology in detecting CIN2+ lesions as summarised in Table 2 . The moderate sensitivity necessitates frequent testing to enable detection of precancerous lesion, which is usually problematic in low income countries for various logistic reasons (Cuzick et al., 2006) . Despite the various operational limitations, few cervical cancer screening programs using cytology have been successful in resource-limited countries, such as "Viet/ American Cervical Cancer Prevention Project", CerviCusco Clinic in Cusco, Peru and similar programs in Kenya and Zambia (Guzzetti et al., 2009; Hassan, 2010; Lin et al., 2011; Suba and Raab, 2012) . These programs emphasize the potential success of screening programs utilizing local manpower trained in performance of screening tests.
Attempts at improving the sensitivity and accuracy of cytology led to introduction of liquid-based cytology (LBC). LBC was aimed at reducing the unsatisfactory rate of cervico-vaginal cytology by providing a more representative sample and overcoming the limiting factors like mucus, blood and excessive inflammation. Various studies showed a significant increase in detection of LSIL or higher cytology on LBC compared to conventional cytology (Díaz-Rosario and Kabawat, 1999; Hatch et al., 2004; Lee et al., 1997) . However, some recent studies have refuted any significant improvement in sensitivity over the conventional Pap test (Ronco et al., 2007) . This combined with prohibitively high cost of the equipment and consumables renders this option less feasible for low-resource settings.
Visual inspection methods
The different visual inspection methods include unaided visual examination ('down-staging'), visual inspection with acetic acid (VIA), visual inspection with Lugol's iodine (VILI) and visual inspection with low-level magnification (VIAM) (Wright et al., 2002) . Unaided visual examination has not been widely accepted or implemented in cervical cancer screening due to its low sensitivity. Over years, visual screening was supplemented by use of acetic acid (VIA) or Lugol's iodine (VILI) to improve the sensitivity of visual detection. Various studies evaluating the test characteristics of VIA have demonstrated sensitivity ranging from 49-86% in cervical cancer screening (Shastri et al., 2005; Sodhani et al., 2006) . Specificity of VIA has been reported to be similar to or slightly lower than cytology, supporting its potential utility in cervical cancer screening. A recent meta-analysis of alternative strategies for cervical cancer screening in sub-Saharan Africa showed a pooled sensitivity and specificity of VIA as 82.4% and 87.4%, respectively. The pooled sensitivity of VILI was higher than VIA (95.1%) but specificity was similar (87.2%). Lesions on VILI were less equivocal and easily recognized by healthcare providers leading to better performance of VILI (Sangwa-Lugoma et al., 2006) . The results of few published meta-analyses on performance of VIA for detection of CIN2+ lesions are tabulated in Table 3 .
Various benefits and limitations of visual detection methods are depicted in Table 1 . Comprehensive competency-based training and regular assessment of test providers is mandatory to improve the specificity of VIA (Blumenthal et al., 2005) . VIA administered by trained personnel for cervical cancer screening in over a lakh women in Bangladesh reaffirmed the sensitivity and specificity as 93.6% and 58.2%, respectively and hence, VIA was suggested as a screening tool for cervical cancer in Bangladesh (Nessa et al., 2010) . The pilot cervical cancer screening program in two districts of Tamil Nadu implemented by World Bank-supported Tamil Nadu Health Systems Project (TNHSP) exemplifies a government-led prevention effort in a resource-limited setting like India. This project utilized VIA/ VILI for screening with referral to secondary level health services for further evaluation. The pilot project had a screening coverage of 73.8% in the target age group. About 56.5% of screen-positive women underwent colposcopy, of whom 7.5% had frank/ invasive carcinoma while 0.87% had CIN2/3 lesions (Tamil Nadu Health Systems Project). However, the screen positivity and follow-up rates were relatively low. An important issue highlighted relating to the project was the requirement of adequate consistent and high-quality training in interpreting VIA results with post-training knowledge and skill assessment. In spite of the limitations, TNHSP pilot has provided evidence for the feasibility and acceptability of cervical cancer prevention via public health system in presence of strong political and administrative support (Krishnan et al., 2013) .
HPV-based testing
Since Human Papilloma Virus (HPV) has been causally linked with majority of the cervical cancers, numerous studies have evaluated HPV DNA testing, either as co-test with cytology or as a standalone primary cervical cancer screening tool. Currently, there are five FDA-approved assays for HPV DNA detection: Hybrid Capture 2 (13 HR-HPV types), Cervista HPVHR test (14 for cytology (Sankarnarayanan et al., 2004b) . The results of published meta-analyses of studies evaluating performance of HPV detection methods as cervical cancer screening tool are highlighted in Table 4 .
The current international guidelines advocate the use of HPV DNA testing in a co-testing approach with cytology (Saslow et al., 2012) , which combines the merits of high sensitivity of HPV DNA testing and better specificity of cytology. This enables an increase of the screening interval in women tested negative with both, without a significant risk of missing precancerous lesions. However, the cost of currently available HPV detection tests precludes the widespread utility of this method in cervical cancer screening in resource-poor settings. Recently, a cost-effective HPV test kit, CareHPV (Qiagen) has been evaluated in low-resource settings. Field evaluation in rural China showed the accuracy of Care HPV to be higher than VIA and approaching that of HC2 (Qiao et al., 2008) . A multi-country evaluation of this test in India, Nicaragua and Uganda also confirmed the high sensitivity (81.5%, 76.5-85.8) and specificity (91.6%) of this test (Jeronimo et al., 2014) . The commercial availability of this test is expected to allow wider applicability of HPV DNA testing HR-HPV types), Cervista HPV 16/18, Cobas 4800 HPV test (PCR-based) and Aptima HPV (amplification-based) assay, (Stoler et al., 2011) .
The main advantages of HPV testing are the high sensitivity (average 95%) ensuring low false-negative rate and a high negative predictive value allowing the screening interval to be extended safely in HR-HPV DNA negative women (Cuzick et al., 2008) . Another potential advantage is the scope of self-collection of samples in order to improve acceptability and screening coverage, especially in low-resource settings. Bhatla et al reported the sensitivity and specificity of HPV-DNA detection for CIN2+ disease to be 82.5% and 93.6% respectively for self-collected samples compared to 87.5% and 93.2% for physician-collected samples (Bhatla et al., 2009 ). These advantages, however, come at the expense of relatively lower specificity. Shastri et al demonstrated HPV DNA testing to be more sensitive than cytology (62% vs 57.4%) but less specific (93.5% vs 98.6%) in detection of CIN2+ cytology (Shastri et al., 2005) . A multicenter study in India showed sensitivity of HPV detection ranging from 45.7-80.9% and specificity between 91.7-94.6% compared to 36.6-72.3% sensitivity and 87.2-98.6% specificity 
Efficacy and Cost-effectiveness of screening modalities in low-resource settings
A cluster randomized controlled trial in India evaluated the efficacy and cost-effectiveness of a single screening round with VIA, cytology and HPV testing in the reducing the incidence and mortality from invasive cervical cancer in rural district. The trial demonstrated higher rates of detection of stage I cancer (53-67% in screened group compared to 19% in control arm) and significantly lower proportion of stage III cancers. The study concluded that VIA was a useful alternative to HPV testing for low-resource settings, provided standardized testing and careful monitoring of test positivity and detection rates are ensured . Cost-effectiveness of the three screening modalities has been evaluated in few studies. A cluster randomized controlled trial in rural India reported VIA to be the cheapest screening strategy at $3.92 per eligible woman followed by cytology at $6.6 and HPV detection at $11.8 per eligible female (Legood et al., 2005) . Goldie et al used computer-based model to assess the cost-effectiveness of cervical cancer screening strategies in five developing countries, including India. The authors demonstrated that strategy of one-visit VIA was the least costly method in India costing about $10 per year of life saved while three-visit cytologic examination was more costly and less effective. An interesting finding was the effect of reduction of cost of HPV detection methods. If the cost of HPV DNA testing was reduced by 50%, two-visit HPV became the most cost-effective strategy overriding one-visit VIA and cost $1 per year of life saved for one screening, $73 for two screenings and $231 for three screenings (Goldie et al., 2005) .
Emerging technologies and Biomarkers
Though HPV DNA tests demonstrate good performance in cervical cancer screening, these tests are not able to differentiate latent from transformative infection. Hence, technologies with ability to detect HPV-induced transformed lesions, such as DNA-based genotyping assays (Roche's Linear Array® and Digene's Luminex®-based HPV genotyping), RNA-based tests (APTIMA® (Gen-Probe), PreTect HPV-Proofer (Norchip, Norway) or NucliSENS Easy Q® (Bio-Mėrieux, France)) and protein-based assays (p16INK4a, Ki-67, P16/Ki67 dual staining, BD ProExC containing MCM2 and TOP2A proteins, interphase FISH for 3q26 gain detection; p63/ p73 staining and PIK3CA) are continually being evaluated for utility in screening of cervical cancer or triage of screen-positive cases (Alameda et al., 2009; Cheung et al., 2010; Cuschieri and Wentzensen, 2008; Goto et al., 2006; Monsonego et al., 2011; Sahebali et al., 2003; Schmidt et al., 2011; Tambouret et al., 2008; van Hamont et al., 2006) . However, the results of most of these assays have not been conclusive and hence, none of these have been recommended for screening or triage. The "ideal" biomolecular marker appropriate for cervical cancer screening still remains elusive.
HPV Vaccination Era: Status of cervical cancer screening
Till recently, cervical cancer control programs had focused on secondary prevention, i.e. screening and early detection of precancerous lesions. However, with the advent of HPV vaccines (Gardasil from Merck & Co. and Cervarix from Glaxo Smith-Kline), primary prevention of cervical cancer seems a distinct reality (World Health Organization 2007) . Currently, majority of these vaccination programs target adolescent girls prior to onset of sexual activity (Schiffman and Wentzensen, 2013) . Hence, it would take expectedly about 30 years to observe the benefits of vaccination once the vaccinated cohorts reach the peak age of occurrence of cervical cancer (Schiffman and Wentzensen, 2013) . However, a significant decline in the rate of high-grade lesions is being reported from countries with ongoing vaccination program including "catch-up" age range of 13-26 years (Brotherton et al., 2011) . The introduction of HPV vaccine in low resource countries has been limited by the high cost of the vaccine. However, efforts by GAVI, the Vaccine Alliance as well as the Gardasil Access Program in low and middle income countries have demonstrated the possibility of inclusion of HPV vaccination at lower cost through funding, provided a strong political and administrative will supports the program (Ladner et al., 2014; Levin et al., 2014) . In India, two states-Delhi and Punjab have launched HPV vaccination recently (World Health Organization 2016). The results of efficacy of vaccination in prevention of cervical cancer shall be known in about three decades in these countries.
Since HPV vaccination is expected to result in significant reduction in cervical precancerous and cancerous lesions, a direct influence on the positive predictive value (PPV) of various screening tests is being speculated. Tota J et al, through their modelling techniques, hypothesized that vaccine-induced reduction in prevalence of precancerous changes would create a situation where cytology screening would not be cost-effective with PPV falling below 10% (Tota et al., 2014) . The prevalence of squamous intraepithelial lesions attributable to HPV 16/18 is expected to decline leading to reduction in PPV (Tota et al., 2014) . Also, decreased "signal-to-noise" ratio (fewer true squamous abnormalities in comparison to inflammation and reactive atypia) is likely to adversely affect the sensitivity and specificity of Pap test. However, a recent study showed a surprisingly small effect of HPV vaccination on PPV of cervical cytology screening (Franco et al., 2009 ). Large-scale prospective studies with strict quality control systems are required to confirm the effect of HPV vaccination on performance of cytology as a primary screening tool. Though studies evaluating the efficacy of HPV testing in vaccinated women are still underway, it is proposed that primary HPV DNA testing with cytology triage would be efficacious combining the sensitivity of HPV and specificity of cytology (Tota et al., 2014) . Apart from the expected cost-effectiveness of this algorithm, another benefit would be the "artificiallyenriched" cytology case load maintaining the diagnostic accuracy of cytotechnologists (Palmer et al., 2016) . Some additional issues that would need consideration in the post-vaccination era include the potential for HPV type replacement (other HPV types taking over after eradication of HPV 16/18) and the possibility of HPV vaccination promoting risky sexual behaviour leading to increase in other HPV genotypes, necessitating continual utility of cytology in screening or triage of HPV-positive women.
Future Directions: The "Operational Framework" model -a guidance document for cancer screening
There is a continuous search for the most appropriate and cost-effective strategy for population-based cervical cancer screening in low-resource countries. The international guidelines (American Cancer Society (ACS), American Society for Colposcopy and Cervical Pathology (ASCCP) and American Society for Clinical Pathology (ASCP)) advocate initiation of cervical cancer screening at the age of 21 years using cytology every 3 years till 30 years of age. Beyond 30 years of age, co-testing with HPV and cytology every 5 years is recommended (Saslow et al., 2012) . These, however, are not applicable in most of the low-resource settings due to various constraints. An appropriate screening algorithm for low-resource countries may include low cost HPV-based testing (as primary or co-testing approach) or VIA if financial constraints prohibit the use of HPV DNA testing.
Recently, the Ministry of Health and Family Welfare of India, a resource-limited country, formulated the screening and management algorithm for population-based screening of cervical cancer along with cancers of breast and oral cavity, the three most common cancer sites in India. The framework proposes institution of awareness and screening activities at the subcentre level, i.e. closest to the population to be screened. It advocates VIA to be used as a screening tool for cervical cancer screening with linkages at higher levels to ensure high quality treatment at affordable costs with regular follow-up. The implementation of this program is intended to be through the existing health system supported by the District NCD (Non-communicable disease) Cell for planning, monitoring and reporting. The states have been given opportunity to implement the program in a phased manner. The sub-centers and primary health centres of the selected districts are to be developed as cancer screening centres and equipped to provide basic services as well as awareness activities. District Hospital and Community Health Centres (CHC) would be equipped for confirmation of screen-positive cases as well as first line management of cases. These centres, in turn, shall be linked to the nearest tertiary level health facility for referral and follow-up as also for mentoring and support. Adequate training and retraining to build competencies at each level of health care facility would be ensured for successful running of the program (Operational Framework. Management of Common Cancers). The 'operational framework' is a guidance document which other resource-constrained countries desirous of implementing cervical cancer screening can replicate with necessary adaptations.
There are still a lot of unanswered questions and challenges ahead viz. determining appropriate cost-effective and point of care screening strategy, deciding intervals of screening, motivation of women to come forward for screening with optimal utilization and augmentation of existing health care infrastructure including diagnostic and treatment facilities. The issues related to implementation of HPV vaccination and applicability of novel biomarkers in triage of HPV-positive women also need to be further explored. The ongoing cervical cancer screening trials, in both developed and developing countries shall address some of these issues. The commercial availability of low-cost HPV DNA test is also expected to boost the efforts of definition of the appropriate screening algorithm for resource-limited countries. The triad of strong political will, judicious allocation of finances, and strategic communication would be the important keys to the success of cancer prevention programming in resource constrained settings.
